Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration With the National Institute on Drug Abuse (NIDA)

Published: Apr 24, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company”, “We” or “Lightlake”), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (“DPMCDA”) of the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), to co-develop a treatment for opioid addiction that utilizes the Company’s innovative proprietary technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news